# A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

> **NCT02760602** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Solanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02760602
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760602, "A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02760602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*